Sfoglia per Autore
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency
2015 Ceccon, M; Boggio Merlo, M; Mologni, L; Varesio, L; Poggio, T; Menotti, M; Bombelli, S; Rigolio, R; Manazza, A; Ambrogio, C; Giudici, G; Casati, C; Compagno, M; Turner, S; Gambacorti Passerini, C; Chiarle, R; Voena, C
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma
2015 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D; GAMBACORTI PASSERINI, C
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783))
2015 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D
Efficacy of a cancer vaccine against ALK-rearranged lung tumors
2015 Voena, C; Menotti, M; Mastini, C; Di Giacomo, F; Longo, D; Castella, B; Merlo, M; Ambrogio, C; Wang, Q; Minero, V; Poggio, T; Martinengo, C; D'Amico, L; Panizza, E; Mologni, L; Cavallo, F; Altruda, F; Butaney, M; Capelletti, M; Inghirami, G; Jänne, P; Chiarle, R
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma
2015 Redaelli, S; Ceccon, M; Pirola, A; Peronaci, M; Gambacorti-Passerini, C; Mologni, L
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
2015 Mologni, L; Ceccon, M; Pirola, A; Chiriano, G; Piazza, R; Scapozza, L; GAMBACORTI PASSERINI, C
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
2015 Fontana, D; Ceccon, M; GAMBACORTI PASSERINI, C; Mologni, L
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells
2014 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D; Gambacorti-Passerini, C
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients
2014 GAMBACORTI PASSERINI, C; Farina, F; Stasia, A; Redaelli, S; Ceccon, M; Mologni, L; Messa, M; Guerra, L; Giudici, G; Sala, E; Mussolin, L; Deeren, D; King, M; Steurer, M; Ordemann, R; Cohen, A; Grube, M; Bernard, L; Chiriano, G; Antolini, L; Piazza, R
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors
2014 Tardy, S; Orsato, A; Mologni, L; Bisson, W; Donadoni, C; GAMBACORTI PASSERINI, C; Scapozza, L; Gueyrard, D; Goekjian, P
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia
2013 Valletta, S; Piazza, R; Redaelli, S; Winkelmann, S; Spinelli, R; Pirola, A; Mologni, L; Donadoni, C; Papaemmanuil, E; Schnittger, S; Dong Wook, K; Boultwood, J; Rossi, F; Gaipa, G; DE MARTINI, G; Francia di Celle, P; Jang, H; Fantin, V; Bignell, G; Magistroni, V; Haferlach, T; Pogliani, E; Campbell, P; Chase, A; Tapper, W; Cross, N; GAMBACORTI PASSERINI, C
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
2013 Mologni, L; Redaelli, S; Morandi, A; Plaza Menacho, I; GAMBACORTI PASSERINI, C
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex
2013 Piazza, R; Magistroni, V; Mogavero, A; Andreoni, F; Ambrogio, C; Chiarle, R; Mologni, L; Bachmann, P; Lock, R; Collini, P; Pelosi, G; GAMBACORTI PASSERINI, C
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
2013 Piazza, R; Valletta, S; Winkelmann, N; Redaelli, S; Spinelli, R; Pirola, A; Antolini, L; Mologni, L; Donadoni, C; Papaemmanuil, E; Schnittger, S; Kim, D; Boultwood, J; Rossi, F; Gaipa, G; DE MARTINI, G; di Celle, P; Jang, H; Fantin, V; Bignell, G; Magistroni, V; Haferlach, T; Pogliani, E; Campbell, P; Chase, A; Tapper, W; Cross, N; GAMBACORTI PASSERINI, C
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
2013 Ceccon, M; Mologni, L; Bisson, W; Scapozza, L; GAMBACORTI PASSERINI, C
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
2012 Redaelli, S; Mologni, L; Rostagno, R; Piazza, R; Magistroni, V; Ceccon, M; Viltadi, M; Flynn, D; GAMBACORTI PASSERINI, C
New developments in the treatment of ALK-driven malignancies
2012 Mologni, L; GAMBACORTI PASSERINI, C
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells
2012 Mologni, L; Brussolo, S; Ceccon, M; GAMBACORTI PASSERINI, C
Inhibitors of the anaplastic lymphoma kinase
2012 Mologni, L
Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells
2011 Marfe, G; Di Stefano, C; Gambacurta, A; Ottone, T; Martini, V; Abruzzese, E; Mologni, L; Sinibaldi Salimei, P; de Fabritis, P; GAMBACORTI PASSERINI, C; Amadori, S; Birge, R
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile